Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Outstanding (Weighted Average) (2018 - 2025)

Historic Shares Outstanding (Weighted Average) for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $94.2 million.

  • Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1763.49% to $94.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.2 million, marking a year-over-year increase of 1763.49%. This contributed to the annual value of $80.8 million for FY2024, which is 3911.07% up from last year.
  • Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $94.2 million in Q3 2025, which was up 1763.49% from $93.8 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $94.2 million during Q3 2025, and its lowest value of $33.0 million during Q1 2021.
  • Over the past 5 years, Crinetics Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $54.3 million (recorded in 2023), while the average stood at $61.5 million.
  • In the last 5 years, Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average) skyrocketed by 333.76% in 2023 and then surged by 4556.98% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $38.4 million in 2021, then soared by 35.24% to $52.0 million in 2022, then increased by 11.71% to $58.1 million in 2023, then skyrocketed by 39.11% to $80.8 million in 2024, then increased by 16.63% to $94.2 million in 2025.
  • Its last three reported values are $94.2 million in Q3 2025, $93.8 million for Q2 2025, and $93.1 million during Q1 2025.